Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing Superkines for cancer and inflammation treatment. While it boasts a strong liquidity position with a current ratio of 4.01 and minimal debt, its financial health is concerning due to negative returns on equity (-47.7%) and assets (-27.1%). The stock price of $0.42 reflects low market confidence, despite the potential of its innovative therapies. Investors should weigh the promising research against the current financial instability and market cap of $34.27M.
Loading financial metrics...
Company is burning $4.3M per quarter with $15.7M in cash. Approximately 3.7 quarters of runway at current burn rate.
Company posted a loss of $-13.8M over the last year, representing Infinity% of revenue.
Operating cash flow has been negative for 3 consecutive quarters, burning $17.0M over the last year.
Fortress balance sheet: cash covers total debt 106×, providing significant financial flexibility.
Excellent liquidity with current ratio of 4.0x ensures operational stability.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (September 30, 2025)